Frequently Asked Questions - JAK Differentiation

Classes Rheumatology Frequently Asked Questions - JAK Differentiation

Instructions

Please Sign in to your account to see the Class.

Introduction

JAK inhibitors are a class of oral drug that’s work from inside the cell to target inflammation that is basis for RA. Baricitinib is a selective JAK1/2 inhibitor licensed for the treatment of patients with RA who are csDMARD-IR and has demonstrated superiority to methotrexate and adalimumab in head-to-head trials. Find out more about mechanism of action of this drug with Prof .Ernest Choy